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ABSTRACT

Characterization of the LKB1-MO25-STRAD AMPKK Complex in
Adult Mouse Skeletal Muscle

Cody D. Smith
Department of Physiology and Developmental Biology
Master of Science

In liver tissue, the AMP-activated protein kinase kinase (AMPKK) complex was
identified as the association of LKB1, MO25α/β, and STRADα/β proteins; however, this
complex has yet to be characterized in skeletal muscle. In this report, we demonstrate the
expression of the LKB1-MO25-STRAD AMPKK complex in adult skeletal muscle, confirm the
absence of mRNA splice variants, and report the relative mRNA expression levels of these
complex-forming proteins. To facilitate this characterization we used control (ctrl) and musclespecific LKB1 knockout (LKB1-/-) mice. LKB1 detection in untreated ctrl and LKB1-/- muscle
lysates revealed two protein bands at approximately 50 and 60 kDa; although, only the heavier
band was significantly diminished in LKB1-/- samples (ctrl: 55±2.5 AU; LKB1-/-: 13±1.5 AU;
p<0.01), suggesting that LKB1 is not represented at 50 kDa as cited previously. Detection of
LKB1 at the higher molecular weight was further confirmed following purification of the
AMPKK complex using polyethylene glycol (PEG) (ctrl: 43±5 AU; LKB1-/-: 8.4±4 AU; p<0.01).
Following ion-exchange-fast protein liquid chromatography (FPLC) the low protein band was
undetectable in ctrl and LKB1-/- fractions. Mass spectrometry of PEG-treated ctrl lysates
confirmed LKB1 protein detection in the 60 kDa protein band while none was detected in the 50
kDa band. Co-immunoprecipitation assays demonstrated associations between all combinations
of LKB1, MO25, and STRAD in LKB1-positive samples, confirming proper complex formation.
Quantitative-PCR revealed significantly reduced expression of MO25α and STRADβ in LKB1-/muscle. Lastly, detection of CaMKKα/β protein in ctrl and LKB1-/- muscle lysates confirmed the
presence of another AMPKK in muscle. Interestingly, CaMKKβ protein is increased in LKB1-/muscle (ctrl: 19±4.3 AU; LKB1-/-: 47±9.2 AU; p<0.05) without an increase in mRNA levels,
suggesting compensation for null LKB1 expression. In all, these findings confirm the presence
of the LKB1-MO25-STRAD complex in adult skeletal muscle, suggest a novel post-translational
modification of LKB1, and identify a potential compensatory mechanism for loss of LKB1
protein in skeletal muscle.
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Introduction
In skeletal muscle, the AMP-activated protein kinase (AMPK) is highly expressed and
plays an integral role in regulating the energy status of the myofiber[1]. AMPK is activated in
myofibers during conditions of energy imbalance, such as contraction, hypoxia, and
hypoglycemia[2]. When activated, AMPK functions to conserve ATP by inhibiting the mTORmediated protein synthesis pathway[3-6], while countering the intracellular energy deficit by
enhancing glucose uptake and fatty-acid oxidation to facilitate ATP production[7, 8]. In doing
so, active AMPK initiates translocation of GLUT-4 and CD36 transporters to the plasma
membrane and inhibits the action of acetyl CoA carboxylase (ACC), thus facilitating carnitinemediated transport of fatty-acids into the mitochondrial matrix[7-10]. Under chronic AMPK
activation, increases in metabolic enzymes and mitochondrial biogenesis have been observed
[11-14]. AMPK is ubiquitously expressed, but is more prominent in tissues of high energy
output/demand (e.g. liver and muscle tissue)[15]. Due to its global expression and ability to
enhance glucose uptake, fatty acid oxidation, and insulin sensitivity, AMPK has become a
popular target for pharmaceutical research to help those suffering from metabolic syndrome,
obesity, and type II diabetes mellitus.
AMPK is activated by a number of different stimuli; however in every case, complete
activation requires phosphorylation at residue T172 on the AMPKα subunit by an upstream
AMPK kinase (AMPKK). To date, four AMPKKs have been identified: LKB1 [16-18],
Ca2+/Calmodulin dependent protein kinase kinase (CaMKK) [19-21], TGF-β activated kinase-1
(TAK-1) [22, 23], and ataxia telengiectasia mutated (ATM) kinase [24, 25]. Originally, LKB1
was thought to be the primary AMPKK in mammalian cells [26, 27]; although recent research
suggests the other AMPKKs may play a larger role than initially thought in specific tissues.
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LKB1 is a tumor-suppressor gene, that when mutated causes Peutz-Jeghers Syndrome [28,
29]. When in association with the scaffold-like, armadillo-repeat protein, mouse protein-25
(MO25) and the pseudokinase, STE-20 related adaptor protein (STRAD), LKB1 phosphorylates
AMPKα at its regulatory T172 site [16-18]. The ubiquitously-expressed protein phosphatase 2C
(PP2C) counters LKB1 phosphorylation by de-phosphorylating AMPKα at the same T172 site
[30-32]. Regulation of these countering enzymes is dependent upon the position of the AMPKβ
N-terminal myristoyl group and the AMP: ATP ratio. When ATP levels are replete, ATP
molecules occupy the AMPKγ-nucleotide binding sites and the AMPKβ myristoyl group is
positioned in proximity to a hydrophobic binding pocket on the AMPKα kinase domain; which
is thought to maintain auto-inhibition of AMPK and enable PP2C activity. During conditions
that increase the AMP: ATP ratio, AMP will replace ATP binding on the AMPKγ subunit and
initiate a positional shift in the β-subunit myristoyl group to enable T172 phosphorylation by
LKB1 and protection from PP2C de-phosphorylation. AMP binding also enhances AMPK
activity via a presumed allosteric mechanism[33]. Therefore, AMP is required for maximal
AMPK activation by LKB1 and protection against deactivation by PP2C.
LKB1 is coded by a gene approximately 23 kb long; it contains 10 exons, nine of which
are coding sequences. Mouse LKB1 protein contains 436 residues (human LKB1: 433 residues)
in which its catalytic region comprises residues ~44-309. Unique to LKB1 is that its catalytic
region poorly resembles the catalytic region of other protein kinases[34]. LKB1 not only
phosphorylates and activates AMPKα 1/2, but has also been reported to phosphorylate and
activate 12 other kinases belonging to the AMPK subfamily [18, 35].
Furthermore, LKB1 is poly-phosphorylated at twelve identified phosphorylation sites;
eight sites are phosphorylated by upstream kinases and three sites are auto-phosphorylated with
2

one site arguably phosphorylated either by autophosphorylation or an upstream kinase.
Upstream kinases include protein kinase A (PKA), ribosomal S6 protein kinase (RSK), protein
kinase C zeta (PKC-δ), possibly the ataxia-telangiectasia mutated (ATM) kinase, and recently,
from the Src family of tyrosine kinases, fyn kinase[34, 36-41]. Interestingly, LKB1 has a
structural T-loop analogous to AMPK, although phosphorylation of the LKB1 T-loop is not
required for activation[42]. Additionally, LKB1 is isoprenylated with a farnesyl group at the Cterminal consensus sequence: Cys-Lys-Gln-Gln[43].
It has been demonstrated that both farnesylation and phosphorylation are required for
LKB1 mediated regulation of cell polarity; however, the role of all twelve putative
phosphorylation sites remains somewhat unresolved[34]. In the presence or absence of LKB1
phosphate groups, both isoforms of STRAD and MO25 are able to interact with each other and
with LKB1[44]. Recently, in endothelial cell lines, phosphorylation of LKB1 at S307 and S428
by PKCδ was shown to be required for proper cytoplasmic localization via the nuclear exportin
proteins, CRM1 and Exportin-7[38, 45]. However, under the same conditions, skeletal and
cardiac muscle cell lines failed to show the same correlation[46]. Phosphorylation of LKB1 at
tyrosines 261 and 365 by Fyn kinase does appear to be important for the proper subcellular
localization of LKB1 in skeletal muscle and adipocytes in vivo. When Fyn is knocked out,
antagonized, or if the phosphorylation sites on LKB1 are mutated, LKB1 remains localized in the
cytoplasm and is able to constitutively phosphorylate AMPK and other members of the AMPK
protein family[41, 47].
STRAD is a true pseudokinase, meaning it has no identified substrates; yet STRAD is
able to bind ATP and exhibits structural motifs characteristic of common protein kinases.
STRAD was actually the first identified substrate of LKB1, being phosphorylated at T329 and
3

T419. From its first discovery, STRAD protein has been implicated as a crucial regulator of
LKB1 activity and proper subcellular localization[29]. Just after the discovery of STRAD,
MO25 was discovered as a key interacting protein in the LKB1-STRAD complex. Structurally,
MO25 resembles the Armadillo Repeat Proteins (ARPs) like β-Catenin and Importin-α which
can function as scaffold-like proteins for protein complexes[48]. Accordingly, MO25 functions
to stabilize the LKB1-STRAD association as LKB1 interacts only weakly with STRAD in the
absence of MO25. In the presence of MO25, the activity of the LKB1-STRAD complex
increases 10-fold [16, 18].
To our knowledge the characterization of the LKB1-STRAD-MO25 AMPKK complex in
adult skeletal muscle has yet to be described. Therefore, the purpose of this report is to verify
the presence of the LKB1-MO25-STRAD complex in skeletal muscle, confirm the absence of
mRNA slice variants, and report the relative mRNA expression levels of these complex forming
proteins in adult mouse skeletal muscle. To facilitate this characterization we used control (ctrl)
and muscle-specific LKB1 knockout (LKB1-/-) mice. By enhanced understanding of the LKB1MO25-STRAD AMPKK complex in skeletal muscle, new insights into AMPK activation are
possible, potentiating the development of better treatments for those suffering from metabolic
pathologies like obesity and type II diabetes mellitus.
Materials and Methods
Animal Care and Generation of LKB1-/- Mouse
The experimental protocols were sanctioned by the Institutional Animal Care and Use
Committee at Brigham Young University. Animal husbandry and development of the muscle
specific LKB1-/- mouse using the Cre/LoxP system of gene splicing were described previously
[49]. Genotyping DNA obtained from mouse ear snips validated successful incorporation of the
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Cre recombinase transgene and floxed LKB1 gene into the mouse genome. Ctrl mice exhibited
the floxed LKB1 gene, but no Cre recombinase; thus, enabling LKB1 expression. Furthermore,
Western blot analysis of mouse muscle samples verified the presence or absence of LKB1
protein detection in ctrl or LKB1-/- mice, respectively.
Muscle Extraction
Both muscle-specific LKB1-/- [49] and ctrl FVB mice were anesthetized with
pentobarbital sodium (0.08 mg/g body weight) into the peritoneal cavity. Upon loss of reflex
activity, mouse gastrocnemii, quadriceps, hamstrings, triceps, and pectoral muscles were
surgically removed, flash frozen between two aluminum blocks in liquid nitrogen, wrapped in
aluminum foil, and stored at -93°C until needed.
AMPKK Purification
In order to characterize the mouse LKB1-MO25-STRAD AMPKK complex, a modified
purification method developed by Hawley et al. in 1996[50], which incorporated methods
developed by Carling et al. in 1989[51], and which have been modified in our lab previously[52],
was used to purify the protein complex. Muscle samples were powdered under liquid nitrogen
using a mortar and pestle. Powdered muscles were weighed and homogenized in 9 volumes of
ice cold (4oC) homogenization buffer (50 mM Tris-HCl, 250 mM Mannitol, 50 mM NaF, 5 mM
Sodium Pyrophosphate, 1 mM EDTA, 1 mM EGTA, 0.02% Brij-35, 10% Glycerol, 1 mM DTT,
1 mM Benzamidine, 1 μg/ml Soybean Trypsin Inhibitor, 0.1 mM Phenylmethanesulfonyl
Fluoride, pH 7.4). The homogenate was centrifuged for 10 minutes at 3000xg. Polyethylene
glycol 6000 (PEG, 25% m/v, CalBioChem, La Jolla, CA) was added to the supernatant to yield a
6% PEG concentration. The solution was well mixed and allowed to stand for 10 minutes on ice.
The 6% PEG homogenate was centrifuged for 10 minutes at 30,000xg and the supernatant was
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collected into a clean centrifuge container. Sufficient 25% PEG was added to yield a 10% PEG
homogenate solution; the solution was mixed well and allowed to stand on ice for 10 minutes.
The 10% PEG homogenate solution was centrifuged for 20 minutes at 30,000xg and the
supernatant was discarded. The pellet was re-suspended in homogenization buffer (0.50ml/g
muscle) by applying a rotating pestle to the pellet on the bottom of the centrifuge tube. The resuspended PEG precipitate solution was centrifuged again for 10 minutes at 30,000xg and the
supernatant was collected. The solution collected from this protocol is termed the PEG lysate.
The PEG lysates were applied to a HiTrap DEAE FF Sepharose (5ml) ion exchange
chromatography column (GE Healthcare Life Sciences, Piscataway, NJ). The column was
washed with homogenization buffer (0.5ml/min) until a baseline absorbance reading of less than
5 AU was obtained. The re-suspended PEG precipitate was injected into the column and
washed with 10mL of homogenization buffer while 1mL fractions were collected. Elution of the
AMPKK complex with 0.2 M NaCl homogenization buffer was performed for 80 minutes while
collecting 1mL fractions. In all, a total of 50-one milliliter fractions were collected.
Protein Detection/Western Blot Analysis
Detection of LKB1 in experimental fractions and lysates was assessed using the Western
blot/ immunodetection procedure described previously [49]. Aliquots (12.5μL) of collected
fractions were diluted in 2X sample loading buffer (12.5μL: 50mM Tris-HCl, pH 6.8, 10%
Glycerol, 2% SDS, 2% β-mercaptoethanol, and 0.1% bromophenol blue) and loaded (25μL/lane)
onto a 10% Tris-Cl gel (Bio-Rad Criterion System, Hercules, CA). Following the membrane
blocking step with 5% nonfat dried milk, the PVDF membranes were probed with an anti-LKB1
antibody (Upstate, cat#: 07-694, Charlottesville, VA, 1:5000; Santa Cruz Biotechnology, Inc,
(M-18) cat#: sc-5640, (D-19) cat#: sc-5638, Santa Cruz, CA, 1:2000) in 1% BSA with
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0.01%NaN3. After overnight incubation, the membranes were washed with TBST and then
incubated with an anti-rabbit IgG streptavidin-horseradish peroxidase (HRP) conjugate antibody
(Jackson ImmunoResearch Laboratories, West Grove, PA, 1:5000) diluted in 1% nonfat dried
milk in TBST. The remaining protocol was followed as described in the aforementioned
citation[49] and all Western blot images were analyzes semi-quantitatively using AlphaEase
software (Genetic Technologies, Miami, FL).
For CaMKKα/β detection in untreated 5% muscle homogenate, isoform-specific
antibodies were used under the same procedure (α-CaMKKα (R-73): cat #: sc11370, 1:2000; αCaMKKβ (L-19): cat#: sc9629, 1:1000; Santa Cruz Biotechnology, Inc, Santa Cruz, CA).
Immunoprecipitation Assays
In order to confirm protein-protein interactions between all possible combinations of
LKB1, MO25, and STRAD, immunoprecipitation followed by Western blot analysis was
performed. Immunoprecipitation assays were carried out using ExactaCruzTM
Immunoprecipitation/Western blot kits purchased from Santa Cruz Biotechnology, Inc (Cat #s:
sc-45038, sc-45040, sc-45041, sc-45043; Santa Cruz, CA). Ten microliters/sample of packed
volume immunoprecipitation matrix was aliquoted into a 1.7 mL microcentrifuge tube. Packed
volume refers to the volume of matrix in the tube after being centrifuged down at 13,000xg for
30 seconds. Following centrifugation, the supernatant was removed and washed with 1 mL of
ice-cold 1x PBS solution. The matrix was centrifuged down again, supernatant removed, and
replaced with 1mL fresh, ice-cold 1x PBS solution. Using the appropriate antibody (α-LKB1
(M18): cat #: sc-5640; α-STRAD (N13): cat #: sc-34102, Santa Cruz Biotechnology, Inc, Santa
Cruz, CA; α-MO25: Custom made, Affinity BioReagents, Inc, Golden, CO), 1.5 μg/sample was
added to the matrix and allowed to rotate end-over-end for at least 2 hours at 4oC.
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After antibody incubation, the matrix was washed three times in ice-cold 1x PBS in the
same manner described above. Following the third wash, enough 1x PBS was added to enable
50 μL aliquots of the desired number of samples under analysis. While vortexing the matrix
after every two aliquots, 50 μL of the matrix suspension was aliquoted into the desired number of
0.65 mL microcentrifuge tubes. The aliquots were spun down to determine equal loading
amounts of matrix and the supernatants were suctioned off. Twenty microliters of sample were
added to corresponding tubes and allowed to rotate over-night at 4oC. Note: the cohesive and
adhesive properties of the matrix/sample solution kept the solution in the bottom of tube, even
while inverted, during incubation. This ensured most efficient diffusion of matrix in the sample
homogenate.
The following day, samples were centrifuged and 20 μL of supernatant was collected into
separate 0.65 mL microcentrifuge tubes for Western blot analysis. The matrix was washed three
times in the same homogenization buffer used in the AMPKK purification protocol. Western
blot analysis was performed on both pellet and supernatant samples as described above with the
additional step of heating the samples at 90oC for 5 minutes after the appropriate volume of
loading buffer was added. Note: the 2X loading buffer prepared for the pellets was diluted to 1X
using dH2O.
Mass Spectrometry
Due to the elusiveness of identifying the protein bands representing LKB1 and STRAD
proteins in Western blot assays, mass spectrometry was used to resolve these uncertainties.
Immunoprecipitation of LKB1 from ctrl PEG lysate was performed as described above.
Following electrophoresis, a coomassie blue (Pierce Biotech, cat#: 24590, Rockford, IL) stain
was applied to the gel for 24 hours. The gel was washed 3 x 1 hour to resolve the bands. The
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bands at presumed LKB1 and STRAD molecular weights were cut from the gel and submerged
in deionized-dH2O in a 1.7 mL microcentrifuge tube. The sample was shipped to the Harvard
based, Taplin Mass Spectrometry Facility, for tryptic-digest mass analysis using an orbitrap mass
spectrometer.
Reverse Transcriptase-Polymer Chain Reaction (RT-PCR)
To test for the existence of variable splice-variant isoforms of LKB1, MO25α/β, and
STRADα/β mRNA expressed in skeletal muscle, RT-PCR was used to study the gene coding
sequences by gel electrophoresis and cycle sequencing. Mouse quadriceps muscles were
harvested as described above; however, immediately following extraction, muscle samples were
submerged in 1mL RNAlater solution (Ambion Inc, Austin, TX) to maintain the integrity of
tissue RNA. Extraction of total tissue RNA was performed using RNeasy Fibrous Tissue Mini
kit (Qiagen, Valencia, CA) according to product instructions. Nano-drop spectrophotometry
was used to determine the approximate total RNA concentration (1 AU at A260 = 40 ng/µL RNA)
and RNA purity (A260/A280 > 1.9). Total RNA integrity was confirmed by detection of sharp and
discrete 28S and 18S RNA bands from total RNA samples run on a borate buffered 1% agarose
electrophoretic gel. After ensuring the extraction of viable RNA, reverse transcription followed
by PCR was performed according to the LongRange 2Step RT-PCR kit instructions (Qiagen,
Valencia, CA).
Primers
Custom primers for RT-PCR, qPCR, and DNA sequencing were purchased from
Invitrogen (Carlsbad, CA) and can be found in Table 1.
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DNA Sequencing
To confirm mRNA expression of the LKB1, MO25α/β, and STRADα/β genes and to test
for variant splice isoforms, DNA sequencing and alignment of the RT-PCR products were
performed. All DNA sequencing was performed using the dideoxy (Sanger) method by the BYU
DNA Sequencing Center. Sequence alignments were performed using Bioedit software (Ibis
Therapeutics, Carlsbad, CA).
Quantitative PCR (qPCR)
To assess the relative mRNA expression levels of LKB1, MO25α/β, STRADα/β, and
CaMKKβ genes between ctrl and LKB1-/- mouse muscle, qPCR was performed using the
following procedure: Primer sets for qPCR were designed for each gene (LKB1, MO25α,
MO25β, STRADα, STRADβ, CaMKKβ and 18s-reference gene) yielding an amplicon length
between 100-300 bp (Table 1). Total RNA from mouse quadriceps muscles was harvested and
determined viable using the same protocol described in RT-PCR. Subsequent cDNA synthesis
was prepared using SuperScriptTM III First-Strand Synthesis SuperMix for qRT-PCR (Invitrogen,
Carlsbad, CA) according to product instructions. Concentration and purity of cDNA were
assessed using nano-spectrophotometry (1 AU at A260 = 50ng/µL, A260/A280 > 1.6, respectively).
Serial dilutions of cDNA used in the optimization assays were made by first adding 1µL of
cDNA to 29µL of RNase/DNase-free water, followed by vortexing and centrifugation. Then,
10µL of this dilution was added to 20µL of RNase/DNase-free water, vortexed and spun down.
The process was repeated with the more diluted sample four additional times to make 6 serial
dilutions total. Serial dilutions were only used within a 6 hour period.
Optimization and gene expression protocols were performed using the SsoFastTM
EvaGreen® Supermix according to product instructions (Bio-Rad, Hercules, CA). Optimal
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primer concentrations were determined for each gene of interest with a reproducible efficiency of
95-105% and r2>0.98 based off the standard curve derived from the cDNA serial dilutions.
Quantitative PCR assays were run using a C1000TM Thermal Cycler/CFX96TM Real-Time
System purchased from Bio-Rad (Hercules, CA).
Quantitative PCR Data Analysis
Using GraphPad software (La Jolla, CA) the relative fluorescence readings for all 50
cycles were fit to a Boltzmann sigmoidal curve for each gene. Interpolation of 40 additional
fluorescence readings was calculated between each cycle from the data. Then, the second
derivative was calculated for each point to reveal the inflection point at which PCR amplification
reached maximal acceleration. The exact cycle number that correlated to this point was defined
as the threshold cycle (CT) for that particular gene.
Averages of the 18S reference gene CT were subtracted from the CT values of LKB1,
MO25α/β, STRADα/β, and CaMKKβ yielding the ΔCT. Average ΔCTs for each gene triplicate
were calculated for each cDNA sample and then averaged again to yield the overall average ΔC T
for each gene. Each gene triplicate average ΔCT for ctrl and LKB1-/- samples was subtracted
from the overall ctrl average ΔCT yielding the ΔΔCT. Normalized gene expression was
calculated by using the 2(ΔΔCT) formula for each ΔΔCT value. Averages and student t-test
calculations were performed on all normalized expression values to demonstrate statistical
significance.
Results
LKB1 is detected primarily at a molecular weight of approximately 60 kDa in adult
skeletal muscle as opposed to 50 kDa, as cited extensively in the literature. Based on its amino
acid sequence, the putative molecular weight of LKB1 is approximately 50 kDa. Western blot
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analysis using two anti-LKB1 antibodies (Anti-LKB1 #1: Upstate, cat#: 07-694, kinase domain
epitope; Anti-LKB1 #2: Santa Cruz Biotech, cat#: sc-5640, C-terminal epitope) of untreated ctrl
and LKB1-/- muscle homogenates detected protein bands representing LKB1 at approximately 50
and 60 kDa, as previously cited [17, 50, 53]. Western blot analysis using a third LKB1 antibody
(Anti-LKB1 #3: Santa Cruz Biotech, cat #: sc-5638, N-terminal epitope) only detected the
heavier protein band. Two different protein molecular weight standards were used (BioRad, cat#:
161-0373; Fermentas, cat#: SM0441) which depicted 50 kDa at slightly different levels. While
the lighter protein band migrated at or above the 50 kDa standard (depending on the protein
standard), the heavy band representing LKB1 was markedly higher than either 50 kDa protein
standard (Fig 1A).
LKB1 protein detected at the higher molecular weight in ctrl tissue lysates was
significantly more intense than LKB1-/- tissue lysates, according to densiometric analysis (ctrl:
55±2.5 AU; LKB1-/-: 13±1.5 AU; p<0.01, n=6, Fig 1B). The small amount of LKB1 detected in
LKB1-/- tissue homogenates is an artifact of non-muscular LKB1 expressing tissue that was
extracted and homogenized with the mouse skeletal muscle (e.g. nerve, adipose, and connective
tissue) or incomplete LKB1 gene splicing by the Cre recombinase.

LKB1 protein detected at

50 kDa was not significantly different between LKB1-/- and ctrl tissue lysates. Based on this
evidence, we propose that LKB1 is primarily represented at a molecular weight of about 60 kDa
in skeletal muscle due to a novel post-translational modification; and while we cannot
completely rule out LKB1 representation at 50 kDa, we assume other non-specific antibody
interactions are taking place.
Following the PEG purification procedure, the heavier protein bands were significantly
more intense in the ctrl PEG lysates compared to the LKB1-/- PEG lysates (ctrl PEG lysate: 43±5
12

AU; LKB1-/- PEG lysate: 8.4±4 AU; p<0.01, n=6, Fig. 1C). Protein band intensity at 50 kDa in
ctrl and LKB1-/- PEG lysates were markedly different, but shy of statistical significance (p=0.07,
n=6). Following FPLC fractionation, LKB1-/- fractions displayed markedly reduced heavy
protein band intensity compared to ctrl fractions; while protein bands at 50 kDa were
undetectable in both fraction sets (Fig. 1D). These data further suggest LKB1 protein is not
significantly represented by the 50 kDa protein band but is the artifact of non-specific proteinantibody interactions.
Tryptic-digest mass spectrometric analysis of extracted 60 kDa protein bands obtained
from gel electrophoresis of ctrl PEG lysates revealed 12 different peptide fragments positively
aligned with the LKB1 amino acid sequence (Fig. 2); two or more positively aligned peptide
fragments confers significant detection. No LKB1 peptide fragments were detected for the 50
kDa band under analysis, possibly due to diminishment of the 50 kDa band following PEG
purification. Regardless, this observation confirms LKB1 representation at a higher molecular
weight than originally expected.
In attempt to identify a novel post-translational modification of LKB1, more mass
spectrometric analysis of the 60 kDa protein band was performed. Other than detection of highly
phosphorylated S31 which was previously established[34], no other post-translational
modifications were detected. It remains unclear what post-translational modification is
responsible for the increased molecular weight of LKB1.
The LKB1-MO25-STRAD AMPKK complex is present in adult murine skeletal muscle.
Co-immunoprecipitation followed by Western blot detection of all possible combinations of
LKB1, MO25, and STRAD proteins revealed positive associations in purified lysates (Fig. 3).
Some LKB1-/- fractions showed positive protein-protein associations and detection of LKB1
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protein presumably from the non-skeletal muscle tissue inadvertently harvested and purified with
muscle extracts or incomplete gene deletion by the Cre recombinase. In all cases, positive
protein detection in LKB1-/- fractions was markedly reduced compared to ctrl fractions;
illustrating disruption of the LKB1-MO25-STRAD complex formation in LKB1-/- mice.
Identification of STRAD protein was initially elusive using Western blot detection with
the anti-STRAD (N-13) antibody. Protein identification was confirmed by tryptic-digest mass
spectrometric analysis of the excised, putative STRAD protein-coomassie stained gel band. Two
different peptide fragments were positively aligned with the mouse STRADα amino acid
sequence confirming positive and significant identification (Data not shown).
Co-immunoprecipitation/Western blot detection assays were performed using antibodies
non-specific for the α/β isoforms of MO25 and STRAD proteins. Hence, determining the
relative composition of MO25 and STRAD isoforms in the AMPKK complex was not assessed
in this project. The data produced from these assays suggest that the LKB1, MO25, and STRAD
proteins comprise an AMPKK complex in skeletal muscle.
CaMKKα/β protein is detected in untreated ctrl and LKB1-/- muscle homogenates by
Western blot analysis. Interestingly, CaMKKβ protein detection was significantly increased in
LKB1-/- untreated homogenates compared to ctrl (ctrl: 19±4 AU; LKB1-/-: 47±9; p<0.05; n=6,
Fig 4B). No difference in CaMKKα protein detection was observed (Fig 4A). This data
suggests that rested and untreated LKB1-/- muscle may compensate for loss of LKB1 by upregulating CaMKKβ protein expression; thus underscoring the predominant and acute role LKB1
plays in skeletal muscle.
RT-PCR followed by DNA cycle sequencing confirmed the expression of LKB1, MO25α/β,
and STRADα/β mRNA in mature mouse skeletal muscle. Custom, gene-specific primers (Table 1)
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for LKB1, MO25α/β, and STRADα/β were used to amplify sections of cDNA ranging in size
from 300-1000+ base pairs in length and spanning multiple exons. Successful PCR products
were sequenced and aligned with their respective mRNA sequences established by the online
National Center for Biotechnology Information (NCBI) database. NCBI accession codes for
each gene used in sequence alignment experiments can be found in Table 1. For every PCR
product detected, only a single band at the putative amplicon size was observed in the agarose
gel following electrophoresis (data not shown); suggesting no variant splice isoform expression
of LKB1, MO25α/β, and STRADα/β mRNA in mouse skeletal muscle. Every gene sequence
was confirmed by amplification of at least two overlapping PCR products spanning the length of
the coding sequence; all of which were identified by a single band on agarose gels.
Quantitative-PCR revealed the relative expression profiles of LKB1, MO25α/β,
STRADα/β, and CaMKKβ in LKB1-/- and ctrl muscle. As expected, there was a small amount of
LKB1 gene expression detected in the LKB1-/- samples due to non-muscular tissue harvested
along with skeletal muscle or incomplete LKB1 gene splicing by Cre recombinase. The nonmuscle derived LKB1 mRNA accounted for 0.31 fold expression compared to ctrl (p<0.01, n=6).
Of the four other genes tested, there was significantly decreased expression of MO25α (ctrl:
1.0±0.06 AU; LKB1-/-: 0.66±0.05 AU; p<0.01, n=6, Fig 5) and STRADβ (ctrl: 1.0±0.07 AU;
LKB1-/-: 0.79±0.06 AU; p<0.05, n=6, Fig 5) mRNA in LKB1-/- muscle compared to ctrl. There
was no difference in STRADα, MO25β, and CaMKKβ mRNA expression between ctrl and
LKB1-/- tissues.
Discussion
The purpose of this study was to verify the presence of the LKB1-MO25-STRAD
complex in skeletal muscle, confirm the absence of mRNA slice variants, and report the relative
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mRNA expression levels of these complex forming proteins in adult mouse skeletal muscle.
Previous studies described a procedure to purify the AMPKK complex from rat liver tissue [17,
50]. We followed a shortened version of the same protocol to successfully purify the AMPKK
protein complex from mouse skeletal muscle. In our purified samples we detected the same
protein constituents comprising the AMPKK complex as determined in rat liver tissue: LKB1,
MO25, and STRAD [17]. Co-immunoprecipitation assays followed by Western blot or mass
spectrometry assays confirmed associations between all combinations of these proteins. In doing
so, we confirmed the accuracy of the AMPKK purification protocols previously cited and
provide supporting evidence that LKB1 is a primary AMPK phosphorylating protein in adult
mouse skeletal muscle.
According to its amino acid sequence, LKB1 has a putative molecular weight of
approximately 50 kDa. One of the first papers published on the AMPKK complex in rat liver
tissue reported the kinase component as a polypeptide of approximately 60 kDa[50]. In a later
paper published by the same group, two Western blot protein bands are identified as LKB1
which are separated by approximately 8-10 kDa; the heavier band migrating as a doublet [17].
Our data confirms this observation. The mass contributed by all 12 identified phosphorylation
sites and farnesylation site cannot account for this 8+ kDa molecular weight difference between
LKB1 bands. Treatment with protein phosphatases-1γ and -2A1 were unsuccessful at
reconciling the molecular weight difference in these bands[17], and treatment with protein
phosphatase-2C reduced the slower-migrating LKB1 doublet to a single band[53]. This data
confirms the different phosphorylation states of LKB1 and suggests other post-translational
modifications besides phosphorylation are responsible for the 8kDa difference between LKB1
protein bands.
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Recognizing the increasing role of ubiquitin in protein regulation, particularly in the
nucleus where LKB1 is localized, and its molecular weight of approximately 8.5 kDa, we tested
LKB1 for the presence of mono-ubiquitination using the Taplin Mass Spectrometry facility at
Harvard. The data from this analysis further confirmed representation of LKB1 protein at 60
kDa; however, no mono-ubiquitinated peptides were observed. Due to the small amount of
LKB1 analyzed by mass spec, the possibility of mono-ubiquitination should not be ruled out
entirely; more analysis is necessary to determine if ubiquitin is involved in the 8 kDa molecular
weight difference in detectable LKB1 protein bands.
Ubiquitin has been demonstrated to play a major role in skeletal muscle regulation. For a
review of ubiquitin function in skeletal muscle, consult the following references [54-57].
Evidence linking ubiquitin to the LKB1-AMPK axis is demonstrated in the finding that AMPK
and ten of the twelve other AMPK-related protein kinases possess structural ubiquitin-associated
(UBA) domains located C-terminal to the kinase domain. The exact function of the UBA
domains characterizing the AMPK related kinases is not well understood; but they are required
for LKB1-mediated phosphorylation and activation. The same group also demonstrated that the
UBA domains do not appear to act as docking sites for the LKB1-MO25-STRAD AMPKK
complex[58].
Mice that are deficient in ubiquitin C-terminal hydrolase-L3 (UCH-L3-/-), an enzyme that
catalyzes the de-ubiquitination of proteins, are resistant to high fat diet induced obesity and
insulin resistance. UCH-L3-/- mice have higher energy expenditure and as a result, lower white
adipose tissue mass. Mediating these effects is increased skeletal muscle AMPK activity and
subsequent increased fatty acid oxidation. This data provides strong evidence for the role of
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ubiquitin in AMPK regulation and that UCH-L3 acts to inhibit AMPK[59]. Further work to
resolve the role of ubiquitin in AMPK regulation is still needed.
Despite increasing evidence for CaMKK and TAK-1 AMPKK activity, our data confirms
LKB1 as a primary upstream kinase of AMPK in skeletal muscle[16, 26]. Some researchers
suggest that the three AMPKKs preferentially phosphorylate different AMPKα subunits which
have different primary regulatory roles. In LKB1-null skeletal and cardiac muscle, AMPKα2
activity is predominantly lost, even in response to AICAR and phenformin, while AMPKα1
activity is only marginally decreased[60, 61]. These data imply that LKB1 predominantly acts
on the AMPKα2 subunit. Since AMPKα2 is the predominant AMPKα subunit expressed in
skeletal muscle[62], it seems likely that LKB1 is the main AMPKK acting on this subunit.
Furthermore, in HeLa cells, which innately lack LKB1, increasing the AMP: ATP ratio or
administering AICAR failed to increase AMPK activation, also suggesting that LKB1 is the
AMPKK responsible for primarily phosphorylating the AMPKα2-subunit in response to AMP
accumulation [17]. Our data confirms LKB1 mRNA and protein expression required to fulfill
this role.
McGee et al. demonstrated that CaMKKα/β protein concentration and activity, and
activating TAK-1 phosphorylation increase in overloaded ctrl and LKB1-/- muscle. These
increases in concentration, activity, and phosphorylation correlate to an increase in AMPKα1
T172 phosphorylation in both muscle genotypes. As a result, increased phosphorylation of
TSC2, a regulatory protein in the TORC1-mediated protein synthesis pathway and target of
AMPK, was observed in overloaded muscle in both genotypes. Downstream targets of TORC1
were also phosphorylated. Chronically activated AMPK also induces increased expression of
GLUT4 and other mitochondrial genes[63]; although these genes were unchanged in ctrl and
18

LKB1-/- overloaded muscle. This evidence suggests that AMPKα1 in skeletal muscle is
preferentially phosphorylated by CaMKKα/β or TAK-1, which increases in concentration and
activity during overload treatment in order to participate in cell growth regulation; but is not as
involved in regulating metabolic adaptations as AMPKα2[27].
While the three AMPKKs may preferentially phosphorylate specific AMPKα subunits,
evidence for redundancies and cross talk between AMPKKs still exists. In 2010, activation of
the CaMKK-AMPK axis was demonstrated in skeletal muscle exposed to a six-day lipid
emulsion treatment. The treatment correlated to increased AMPK and acetyl-CoA carboxylase
(ACC) phosphorylation, increased ACCβ and adiponectin receptor 1 mRNA levels, and
increased PPARγ-coactivator-1α (PGC-1α) protein levels. Significantly greater association
between CaMKK and AMPK was also observed, while association between LKB1 and AMPK
remained unchanged; furthermore, the levels of ATP were unchanged in the lipid emulsion and
control treated mice[64]. Unfortunately, the AMPKα subunit was not specified in this study;
however, the data demonstrates the ability of CaMKK to also regulate AMPK-mediated lipid
metabolism and mitochondrial gene expression and biogenesis pathways, and not just cell
growth. Certainly, our data showing increased CaMKKβ protein levels in LKB1-/- muscle may
be indicative of cellular compensation to activate AMPK and potentiate its metabolic effects.
While CaMKKβ protein expression was significantly increased in LKB1-/- muscle,
CaMKKβ mRNA expression remained unchanged. Therefore, the increase in CaMKKβ protein
is the result of either enhanced CaMKKβ mRNA translation or decreased proteosomal
degradation of CaMKKβ protein in LKB1-/- muscle. Further work is required to elucidate the
mechanisms responsible for increased CaMKKβ protein content in LKB1-/- skeletal muscle.
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Some researchers suggest that CaMKK and TAK-1 are AMPKKs employed to prepare
the cell for an upcoming energy imbalance which might be the case in the lipid emulsion treated
muscle[26]. While further work is required to uncover the full function of CaMKK and TAK-1
as AMPKKs in skeletal muscle, LKB1 remains the primary AMPKK responsible for AMPKα2
activation under acute increases in the AMP: ATP ratio.
Previous studies have demonstrated that formation of the heterotrimeric LKB1-MO25STRAD protein complex is imperative for proper LKB1 localization out of the nucleus into the
cytoplasm [29, 44, 65]. Interestingly, both STRAD and MO25 can freely cross the nuclear
membrane. In the nucleus, association with STRADα facilitates LKB1 binding with the nuclear
export proteins, CRM1 and Exportin-7. Likewise, at the cytosolic face, association with
STRADα prevents LKB1 from associating with the nuclear import protein, Importin-α.
STRADβ, however, has not been demonstrated to participate in LKB1 shuttling. The function of
MO25 was originally thought to facilitate LKB1 nuclear translocation as its structure resembles
the family of nuclear transport proteins, karyopherins; however, no data supports this case.
MO25 simply enhances the association between STRADα and LKB1[66].
In addition to coordinating proper sub-cellular localization, association with MO25 and
STRAD is also responsible for optimal LKB1 activity [16-18]. This was confirmed by
resolution of the LKB1-MO25α-STRADα and MO25α-STRADα crystal structures. Remarkably,
the pseudokinse, STRADα binds ATP and adopts the active, “closed” kinase conformation, but
is yet unable to phosphorylate downstream targets due to the substitution of crucial catalytic
amino acid residues. Association with MO25α enhances the STRADα-ATP interaction and vice
versa. Interaction with MO25α or ATP is essential for maintaining STRADα in the closed
conformation; and subsequently essential for LKB1 activation. Mutated STRADα, incapable of
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binding ATP or MO25, is unable to activate LKB1; although, complex formation still occurs[67].
Analysis of the trimeric protein structure reveals STRADα, in its closed conformation, binding
LKB1 as a pseudo-substrate. Association with STRADα and MO25α maintains the closed and
active conformation of LKB1. MO25α actually interacts with and stabilizes the LKB1 activation
loop[68]. These reports suggest LKB1 kinase activity is regulated by allosteric conformational
shifts dependent on its association with MO25 and STRAD proteins.
Collectively, the crystal structure data and nuclear transport data reveal two redundant
mechanisms of LKB1 activation: proper subcellular localization and structural shifts that render
LKB1 in the active and closed kinase conformation. Both regulatory mechanisms are dependent
on association with MO25 and STRAD proteins. This data is consistent with previous reports of
enhanced LKB1 activity and proper localization when in complex with MO25 and STRAD [1618, 69].
As mentioned, the gene sequencing data of this study revealed no alternate splice variants
of LKB1, MO25, and STRAD proteins. In a previous report, an alternate splice variant of LKB1
mRNA was identified in rodent and human tissues. The two spice isoforms exhibit differential
ninth exon incorporation into the mRNA, which leads to a long and short version of LKB1. The
LKB1-long splice variant (LKB1L) is the predominant form of LKB1 mRNA translated in cells.
Translation of the LKB1-short splice variant (LKB1S) mRNA results in substitution of the
previously identified C-terminal 63 amino acid residues with an alternate 39 residues. Both
isoforms are widely expressed and able to phosphorylate AMPK and other members of the
AMPK-protein family. It is unclear what specific roles there splice variants may play; although,
male mice lacking LKB1S in the testis were reproductively sterile, suggesting a crucial role of
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LKB1S in gametogenesis [70]. Our gene sequencing data only detected the LKB1L isoform
suggesting the LKB1S isoform is not expressed in mouse skeletal muscle.
In a study by Marignani et al, 11 novel splice variants of STRADα mRNA were reported;
although all were identified in human cancer cell lines and all of them disrupted proper LKB1
activity and localization due to lack of complex formation[69]. To our knowledge there have
been no reports of alternative splice variants of MO25α/β proteins. Likewise, our data confirmed
no splice variant expression of STRAD and MO25 mRNA in mouse skeletal muscle.
While LKB1-/- tissue exhibited significant decreases in MO25α and STRADβ gene
expression, the role LKB1 may play in regulating gene expression remains unclear. More
experimentation using the muscle-specific LKB1 knockout mouse is necessary in this regard.
In this study, specific characteristics of the LKB1-MO25-STRAD AMPKK complex in
skeletal muscle have been elucidated. Our results confirm the presence of the LKB1- MO25STRAD AMPKK complex in mouse skeletal muscle, verify the mRNA coding sequence of each
protein expressed and the absence of alternative splice variant expression, and reveal the relative
mRNA expression profile of LKB1, MO25α/β, STRADα/β, and CaMKKβ genes comparing ctrl
and LKB1-/- muscle. Notably, this report provides evidence that LKB1 is actually detected at a
molecular weight of approximately 60 kDa and not 50 kDa in skeletal muscle. We propose that
an unidentified post-translation modification is responsible for this increase in molecular weight.
Determining the identification of this protein modification in correlation with further
characterization of the LKB1-MO25-STRAD AMPKK complex in skeletal muscle may facilitate
new insights into the LKB1-AMPK axis of metabolic regulation and possibly provide new
avenues for anti-diabetic drug design.
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Table 1
Custom primer sequences for (A) PCR and DNA sequencing and (B) quantitative PCR assays.
A.)
Forward
Primers

bp start

NCBI
Accession

Gene

Primer (5'-3')

LKB1

CTTGAAAAGAATTGGCGCTC

31

GGCGAGCTGATGTCGGTGGG

125

CCACCGCATCGACTCCACCG

160

GTCAAGCAGGTAGAGTGCCG

376

ACGGGGACGGAGACGAAGCA

325

AGATGCAGACTCCAGATTGGCG

119

TCGACATGAGCCACTTGCCA

735

STRADα

ATGTCTTTTCTTGCCAAT

128

NM_028126

STRADβ

CTGGAGAGTCGCTGGCCTTG

249

NM_172656

CTGTTGGCAGCTGGCTTTGG

755

MO25α
MO25β

AAGCACGGACAAAGGCATAG

1006

TGGTGCAGCTGTGTTTGCAG

1409

Reverse
Primers
LKB1

MO25α
MO25β
STRADα
STRADβ

bp start
ACAGCGAAAGGGTGCAGGGC

699

TCCACAGCGAAAGGGTGCAGG

702

AGGTACGAGCGCCTCAGCCA

1045

GTCCCGAAGTGAGTGGACAG

1483

AGCTACCAGGGTGCCGAGGAG

673

ACGTTCTCCAACCTGGACTG

1604

ACACACTGGGCAAGGGAGAC

1345

AATTGTGGCGGTCCAGGATCA

1009

ATCGTGGACTGCACGCTGCC

713

CCTGAGCTCACACAACAGGA

1561

AGCCAGCTGCCAACAGTGAA

770

CGGCTGCACTGATGTGCTGA

1068

TCCTGGCTTTCTTCTTTCATCTG

1508

CGAGGAAGTCGTGCGGGTGC

1831

35

NM_011492

NM_133781
NM_026908

B.)
Gene
LKB1

F/R
F
R
MO25α F
R
MO25β F
R
STRADα F
R
STRADβ F
R
CamKKβ F
R
18S
F
R

Primer
bp start PL
TTGGGCCTTTTCTCCGAGG
107
138
CAGGTCCCCCATCAGGTACT
244
CCGTTCCCATTTGGCAAGTCT
422
160
ACAGAATTTCTTTCATGGCGACC
581
CAAAACGCAGCCTATCGTGGA
1140
94
CTCGTCGTCTGTCCTTTCTTTC
1233
TTCCCTCTGTTCCCATGTCC
1687
118
AGTCCCAGCCTTAACTGACC
1804
CCTTACGCTGTGGGATTATGC
701
111
TGGACAGCTCAACATACTTGAAG
811
GCCATGGGTGTGACGCTGTA
1173
116
GGCTGGTCGGGAAACTCCAG
1288
GTGCATGGCCGTTCTTAGTTG
1328
133
GCCACTTGTCCCTCTAAGAAGTTG
1460
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Figure 1
LKB1 protein is detected at a molecular weight of approximately 60 kDa, and not 50 kDa. (A) LKB1
protein detection in untreated muscle lysates using three different anit-LKB1 antibodies (Anti-LKB1 #1:
Upstate, cat#: 07-694, kinase domain epitope; Anti-LKB1 #2: Santa Cruz Biotech, cat#: sc-5640, Cterminal epitope; Anti-LKB1 #3: Santa Cruz Biotech, cat #: sc-5638, N-terminal epitope) and two
different protein molecular weight standards (BioRad, cat#: 161-0373; Fermentas, cat#: SM0441,
identified in parentheses). Untreated muscle lysates were prepared by homogenizing mouse gastroc
muscles in enough lysate buffer to make a 5% homogenate using a rotating pestle. Enough sample
volume was mixed with the appropriate amount of loading buffer and ddH2O to allow approximately
90μg of protein to be loaded into each gel well. (B) Quantification by densiometric analysis of LKB1
detection using the Anti-LKB1 #1 antibody. Western blot images were scanned and loaded into
AlphaEase software which was used to quantify relative band intensities. (C) LKB1 protein detection in
PEG lysates using the Upstate anti-LKB1 antibody. PEG-lysates were obtained by adding enough 25%
PEG (m/v) to achieve a 10% PEG concentration in muscle lysates. Centrifugation caused precipitation of
PEG and the AMPKK complex. The precipitate was re-suspended in lysate buffer to reconstitute the
AMPKK complex. (D) LKB1 detection in FPLC fractions using the Upstate anit-LKB1 antibody. FPLC
fractions were collected as PEG lysates were applied to a DEAE FF Sepharose ion-exchange
chromatography column, eluted with 200 mM NaCl Buffer B. Protein bands at 50 kDa were undetectable
in FPLC fractions. In all charts, * = p<0.01 compared to ctrl 60 kDa protein band intensity.
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Figure 2
Tryptic-digest mass spectrometric analysis of the 60 kDa protein band detected the following peptide
sequences from the LKB1 amino-acid sequence. Twelve separate peptide fragments were detected in all.
Prior to analysis, ctrl PEG-lysates were immunoprecipitated using anti-LKB1 antibody (Santa Cruz

Biotech: (M-18), cat#: sc-5640). After gel electrophoresis, a Coomassie blue stain was applied to the
gel and allowed to incubate over-night. Gel bands at the putative molecular weights were excised from
the gel and analyzed by mass spectrometry.

12 Peptide Fragments Detected by Mass Spectrometry Align with the LKB1 Aminoacid Sequence
MDVADPEPLG
GKVKEVLDSE
EKQKMYMVME
NLLLTTNGTL
AGVTLYNITT
RQIRQHSWFR
DGIIYTQDFT
VCSSNKIRRL

LFSEGELMSV
TLCRRAVKIL
YCVCGMQEML
KISDLGVAEA
GLYPFEGDNI
KKHPLAEALV
VPGQVLEEEV
SACKQQ

GMDTFIHRID
KKKKLRRIPN
DSVPEKRFPV
LHPFAVDDTC
YKLFENIGRG
PIPPSPDTKD
GQNGQSHSLP

STEVIYQPRR
GEANVKKEIQ
CQAHGYFRQL
RTSQGSPAFQ
DFTIPCDCGP
RWRSMTVVPY
KAVCVNGTEP

KRAKLIGKYL
LLRRLRHRNV
IDGLEYLHSQ
PPEIANGLDT
PLSDLLRGML
LEDLHGRAEE
QLSSKVKPEG

MGDLLGEGSY
IQLVDVLYNE
GIVHKDIKPG
FSGFKVDIWS
EYEPAKRFSI
EEEEDLFDIE
RPGTANPARK

**Note: No peptide fragments detected in the 50 kDa protein band aligned with the LKB1 amino acid
sequence.
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Figure 3
FPLC fractions containing LKB1 protein show positive LKB1-MO25-STRAD associations, suggesting
complete complex formation. Co-immunoprecipitation followed by Western blot assays demonstrated
positive associations between all combinations of LKB1, MO25, and STRAD proteins. Representative
blots were chosen based on the ctrl FPLC fraction exhibiting the highest protein detection. Ctrl and
LKB1-/- fractions were assayed side-by-side.
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Figure 4
(A) CaMKKα and (B) CaMKKβ protein was detected in untreated muscle lysates, demonstrating the
presence of other AMPKK protein expression in skeletal muscle. Untreated muscle lysates were prepared
by homogenizing mouse gastroc muscles in enough lysate buffer to make a 5% homogenate using a
rotating pestle. * = p<0.05 compared to ctrl.
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Figure 5
The relative gene expression profile in ctrl and LKB1-/- skeletal muscle was determined using
quantitative-PCR. Custom, gene-specific primers, yielding average amplicons of 100-200 bp in length
were used to determine the relative mRNA expression levels of LKB1, MO25α/β, STRADα/β, and
CaMKKβ genes; 18S amplification was used as the reference for normalization calculations. Proper
optimization procedures were performed prior to analysis as described in the experimental procedures
section. * = p<0.01 compared to ctrl; + = p<0.05 compared to ctrl.
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